Approach to the Patient: Diagnosis of Cushing Syndrome
Open accessThe DOI matches its Crossref record; 96 of the 100 references it cites were found in a registry or an index; 50 of the 202 sources its claims cite were checked for support.
Abstract
Cushing syndrome results from supraphysiological exposure to glucocorticoids and is associated with significant morbidity and mortality. The pathogenesis includes administration of corticosteroids (exogenous Cushing syndrome) or autonomous cortisol overproduction, whether or not ACTH-dependent (endogenous Cushing syndrome). An early diagnosis of Cushing syndrome is warranted; however, in clinical practice, it is very challenging partly because of resemblance with other common conditions (ie, pseudo-Cushing syndrome). Initial workup should start with excluding local and systemic corticosteroid use. First-line screening tests including the 1-mg dexamethasone suppression test, 24-hour urinary free cortisol excretion, and late-night salivary cortisol measurement should be performed to screen for endogenous Cushing syndrome. Scalp-hair cortisol/cortisone analysis helps in the assessment of long-term glucocorticoid exposure as well as in detection of transient periods of hypercortisolism as observed in cyclical Cushing syndrome. Interpretation of results can be difficult because of individual patient characteristics and hence requires awareness of test limitations. Once endogenous Cushing syndrome is established, measurement of plasma ACTH concentrations differentiates between ACTH-dependent (80%-85%) or ACTH-independent (15%-20%) causes. Further assessment with different imaging modalities and dynamic biochemical testing including bilateral inferior petrosal sinus sampling helps further pinpoint the cause of Cushing's syndrome. In this issue of "Approach to the patient," the diagnostic workup of Cushing syndrome is discussed with answering the questions when to screen, how to screen, and how to differentiate the different causes. In this respect, the latest developments in biochemical and imaging techniques are discussed as well.
Overview
CoChat Summary
## TL;DR
This article is a clinical review of how to diagnose Cushing syndrome, emphasizing when to screen, how to interpret first-line tests, and how to distinguish pseudo-Cushing, ACTH-dependent, ACTH-independent, and pregnancy-related cases. It uses two cases to illustrate common diagnostic pitfalls, including anticonvulsant interference with dexamethasone testing and intermediate ACTH values that require additional biochemical and imaging workup.
## Key findings
- Cushing syndrome is associated with serious morbidity and mortality; the paper states a 3.5 to 5 times increased mortality risk versus the general population, and the risk of myocardial infarction is about 4.5 times higher.
- Endogenous Cushing syndrome is estimated to have an incidence of 0.2 to 5.0 per million people per year and a prevalence of 39 to 79 per million; 80% to 85% of cases are ACTH-dependent and 15% to 20% are ACTH-independent.
- First-line screening tests recommended are 1-mg dexamethasone suppression test (DST), 24-hour urinary free cortisol (UFC), and late-night salivary cortisol (LNSC); UFC and LNSC should be done at least twice because of day-to-day variation.
- In the hair-cortisol section, the paper reports hair cortisone had 87% sensitivity and 90% specificity, compared with hair cortisol at 81% sensitivity and 88% specificity, for distinguishing Cushing syndrome in the cited studies.
## Methods
- This is an expert clinical review in the “Approach to the Patient” format, organized around diagnostic questions: when to screen, how to screen, and how to differentiate causes of Cushing syndrome.
- The paper draws on two illustrative cases: case 1 involved a 45-year-old woman with suspected pseudo-Cushing syndrome and case 2 a 52-year-old woman with adrenal imaging findings, venous thrombosis, and ultimately pituitary-dependent Cushing syndrome.
- The main analysis is a narrative synthesis of diagnostic strategies using biochemical tests (DST, UFC, LNSC, ACTH, DHEAS, CRH testing, dexamethasone-CRH testing), imaging (pituitary MRI, adrenal CT/MRI, PET), and bilateral inferior petrosal sinus sampling.
## Limitations
- The paper states that all tests have caveats and interpretation requires awareness of individual patient characteristics and test limitations.
- It explicitly notes that the hair cortisol/cortisone method is not yet widely available and is still a relatively novel diagnostic tool.
- Evident from the text: this is a review with illustrative cases, not a primary diagnostic accuracy study of all recommended tests, so some performance figures are drawn from cited prior studies rather than generated directly in this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
39 Valid · 2 Not valid · 70 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ACTH-dependent CS accounts for 80% to 85% of cases and ACTH-independent accounts for 15% to 20% (2, 4, 5).”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > Learning points
What the sources say
- Not checked — no full text of the sourcecites [2] Lacroix, 2015, Cushing’s syndrome, Lancet source
- Not checked — no full text of the sourcecites [4] Pivonello, 2008, Cushing’s syndrome, Endocrinol Metab Clin North Am source
- Partly supportedcites [5] Sharma, 2015, Cushing’s syndrome: epidemiology and developments in disease management, Clin Epidemiol sourceExperimental — accuracy not yet measured
The Classification of Cushing’s syndrome section states that ACTH-independent disease accounts for 15%–20% of endogenous Cushing’s syndrome in adults. The citing sentence gives the same percentage but does not specify those limits, so the source does not establish it for all Cushing syndrome cases. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“ACTH-dependent CS accounts for 80% to 85% of cases and ACTH-independent accounts for 15% to 20% (2, 4, 5).”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > Learning points
What the sources say
- Not checked — no full text of the sourcecites [2] Lacroix, 2015, Cushing’s syndrome, Lancet source
- Not checked — no full text of the sourcecites [4] Pivonello, 2008, Cushing’s syndrome, Endocrinol Metab Clin North Am source
- Supportedcites [5] Sharma, 2015, Cushing’s syndrome: epidemiology and developments in disease management, Clin Epidemiol source
The Classification of Cushing’s syndrome section states directly that ACTH-dependent disease accounts for 80%–85% of cases. Its context specifies endogenous Cushing’s syndrome. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients often present with nonspecific features such as (abdominal) obesity and weight gain, rounded (moon) face, menstrual irregularity, and depression (1, 3, 5) as depicted in Figure 1.”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > When to Screen
What the sources say
- Not matchedcites [1] Agrawal, 2021
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites [3] Nieman, 2008, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab. source
Section 1.0 says patients more often have features common in the general population, including obesity, depression, and menstrual irregularity. Table 1 also lists weight gain and facial fullness among common or less discriminatory features of Cushing’s syndrome, supporting the description of nonspecific presentation. Page numbers are not provided in our copy. (LLM, conf=0.89)
- Partly supportedcites [5] Sharma, 2015, Cushing’s syndrome: epidemiology and developments in disease management, Clin Epidemiol sourceExperimental — accuracy not yet measured
The Clinical features section identifies weight gain as the most common sign, says increased visceral adipose tissue is common, and describes menstrual irregularity and depression in patients with Cushing’s syndrome. It also says no single symptom is pathognomonic, consistent with the claim that these features are nonspecific. The passages from our copy do not mention a rounded or “moon” face. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“Regarding the 1-mg DST, it is essential to screen for current drug use, which could alter dexamethasone clearance and/or levels of cortisol-binding globulin.”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > How to Screen/Establishment of Hypercortisolism
What the sources say
- Supportedcites [3] Nieman, 2008, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab. source
The Remarks for dexamethasone tests state that anticonvulsants including phenytoin and carbamazepine increase dexamethasone clearance, affecting the 1-mg DST. The same section says oral contraceptives increase cortisol-binding globulin and can cause false-positive results. Page numbers are not shown in the supplied passages. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These relations between corticosteroid use and cardiometabolic sequelae seemed to be related to glucocorticoid receptor gene variants that are associated with increased or normal glucocorticoid sensitivity.”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > Exogenous Steroids
What the sources say
- Could not verifycites [37] Savas, 2017, Associations between systemic and local corticosteroid use with metabolic syndrome and body mass index, J Clin Endocrinol Metab. sourceExperimental — accuracy not yet measured
Our copy of Savas et al. (2017) reports the associations between corticosteroid (CS) use and cardiometabolic traits (metabolic syndrome, BMI), especially in women and in systemic/inhaled users (Discussion; Sensitivity analyses), but it nowhere attributes those relations to glucocorticoid receptor gene variants. The mechanisms it does discuss are non-genetic: sex differences in susceptibility, drug absorption/distribution/metabolism/elimination, adherence, CS-induced reductions in estrogen and testosterone, visceral/gynoid fat distribution, and the high receptor affinity and pharmacokinetics of budesonide/fluticasone (Discussion, refs 14-35). Searches for 'glucocorticoid receptor gene variants', 'polymorphism/genetic variation in sensitivity', and 'NR3C1 / individual susceptibility / limitations' returned no passage on genetic glucocorticoid sensitivity; the Study design section mentions the cohort's 'complex genetics' focus only in describing Lifelines, and the Limitations paragraph lists cross-sectional design, confounding by indication and residual confounding, not genotype. (LLM, conf=0.72)
- Partly supportedcites [38] Savas, 2020, Systemic and local corticosteroid use is associated with reduced executive cognition, and mood and anxiety disorders, Neuroendocrinology sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports an association between corticosteroid use and adverse cardiometabolic outcomes. Neither that passage nor the Discussion's account of systemic effects links those outcomes to glucocorticoid receptor gene variants or to increased or normal glucocorticoid sensitivity; searches for those terms found no such passage. (LLM, conf=0.83)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
76 more claims · 24 with their cited sources checked
Create a free account to see all 129 claims and to verify the 46 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 10
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 10×
“Patients who have multiple symptoms, which are progressive over time, in particular when specific cushingoid features are present (3).”
BackgroundInfluentialMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Moreover, it is also important to screen for concomitant use of other drugs such as antifungals, protease inhibitors, or estrogens given the potential drug–drug interaction resulting in increased glucocorticoid effect (32, 33).”
BackgroundChronic stress and comfort foods: Self-medication and abdominal obesity
Dallman, M. F., Pecoraro, N. C., & la Fleur, S. E. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2004.11.004 · Cited by 656
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Research works printed but not linked: 1
- Agrawal, 2021, The Human Hypothalamus, 185
Cited by
Gadelha, M., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 168
Ceccato, F., Barbot, M., Mondin, A., Boscaro, M., Fleseriu, M., & Scaroni, C. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac686 · Cited by 51
Determination of cortisone and cortisol in human scalp hair using an improved LC-MS/MS-based method
Mirzaian, M., van Zundert, S. K. M., Schilleman, W. F., Mohseni, M., Kuckuck, S., van Rossum, E. F. C., van Schaik, R. H. N., & van den Berg, S. A. A. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0341 · Cited by 41
Self-citationEmerging diagnostic methods and imaging modalities in cushing’s syndrome
Wright, K. E., van Rossum, E. F. C., Zan, E., Werner, N. L., Harris, A. G., Feelders, R. A., & Agrawal, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230447 · Cited by 33
“, diltiazem and fluoxetine) can prolong dexamethasone bioavailability, which can suppress ACTH production by adenomas that are sensitive to negative feedback and thus lead to false-negative results (13, 20).”
BackgroundResultInfluentialSelf-citationEpigenetic Mechanisms Modulated by Glucocorticoids With a Focus on Cushing Syndrome
Paes, T., Feelders, R. A., & Hofland, L. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae151 · Cited by 24
Self-citation
Metadata
- Authors
- Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A.
- Affiliations
- Erasmus MC (NL)
- NYU Langone Health (US)
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-08-29
- Volume
- 107
- Issue
- 11
- Pages
- 3162-3174
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC9681610
- OpenAlex
- W4293457641
- Cited by
- 91
- References
- 100
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 17 · 2023: 12 · 2022: 2
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, endogenous Cushing syndrome, dexamethasone suppression test, 24-hour urinary free cortisol, late-night salivary cortisol, ACTH-dependent Cushing's syndrome, ACTH-independent Cushing's syndrome, plasma ACTH, inferior petrosal sinus sampling, hypercortisolism
- MeSH terms
- Cushing Syndrome, Diagnosis, Differential, Glucocorticoids, Humans, Hydrocortisone, Petrosal Sinus Sampling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approach to the Patient: Diagnosis of Cushing Syndrome. https://app.cochat.ai/papers/10.1210/clinem/dgac492
- The paper
- Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022). Approach to the Patient: Diagnosis of Cushing Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac492
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.